Home > Worldwide > Takeda UK Limited
Main contents starts here
Takeda UK Limited
| Home page | |
|---|---|
| Business | Marketing |
| Key Products | Actos® (pioglitazone hydrochloride) |
| Amias® (candesartan cilexetil) | |
| Address | Takeda House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, UK |
| Telephone | +44(0)1628 537900 |
| Facsimile | +44(0)1628 526615 |
| Contact | |
| Founded | 1997 |
Takeda UK was established in 1997 to coincide with the launch of Candesartan cilexetil (Amias®), an angiotensin receptor blocker (ARB), which is now the UK's second most prescribed ARB.
In November 2000 Takeda UK launched another new compound, Pioglitazone (Actos®), a member of the Thiazolidinedione (TZD) class for treating type 2 diabetes.
The success of the Pioglitazone launch resulted in Takeda UK jointly winning the prestigious Pharmaceutical Company of the Year section at the 2001 Pharmaceutical Marketing Effectiveness Awards.
In 2005 Takeda UK were finalists in both the Company of the Year, and Company of the Year (<£100m) sections at the Pharmaceutical Marketing Effectiveness Awards.
[*]The information presented at each company's website is governed by laws and regulations of that particular country, and therefore is intended for residents in that country only.
Photo
